Last edition
News about "Agilent Technologies"
PD-L1 IHC 22C3 pharmDx gains CE-marked indication to identify eligible patients with epithelial ovarian, fallopian tube and primary peritoneal carcinoma for pembrolizumab treatment.
Agilent Technologies | 27/07/2026 | By News Bureau
Agilent Technologies has received FDA approval to expand the use of its PD-L1 IHC 22C3 pharmDx test on the Dako Omnis platform, broadening access to PD-L1 testing for four additional tumour types and supporting streamlined pathology laboratory operations.
Agilent Technologies | 05/06/2026 | By News Bureau | 181
Agilent Advances Sustainable Science with New India Refurbishment Centre
Agilent Technologies has inaugurated a new refurbishment centre in India, reinforcing its commitment to sustainable science and affordable innovation while enhancing customer engagement through an integrated, green-certified facility that also houses a dedicated education centre.
Agilent Technologies | 18/12/2025 | By News Bureau | 344
Agilent Technologies, Lunit Partner to Develop AI-Powered Companion Diagnostic Tools
Agilent Technologies has entered into a nonexclusive collaboration with Korea-based Lunit to develop AI-based companion diagnostic solutions.
Agilent Technologies | 23/09/2025 | By Dineshwori | 298
Agilent Technologies Unveils New Biopharma Experience Center in Hyderabad
Agilent Technologies has launched a new Biopharma Experience Center in Hyderabad, Telangana, as part of its broader three-to-five-year India growth strategy.
Agilent Technologies | 30/07/2025 | By Dineshwori | 341
Agilent Announces Acquisition of BIOVECTRA
With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.
Agilent Technologies | 24/09/2024 | By Aishwarya | 705
Agilent Launches Biopharma CDx Services Lab to Accelerate Precision Medicine
The BCSL and Agilent’s assay development model will support drug development from early clinical studies through regulatory approval with efficient, flexible, and streamlined companion diagnostic development.
Agilent Technologies | 10/09/2024 | By Aishwarya | 1022
Agilent Technologies to spend $725 M to double production capacity of therapeutic nucleic acids
Two new manufacturing lines—called Trains C and D—will be added to the company’s Frederick, Colorado, facility
Agilent Technologies | 11/01/2023 | By Sudeep Soparkar | 1026
Agilent Technologies to organise Future Lab Summit in Ahmedabad
The summit will showcase an array of Agilent’s future-ready analytical solutions
<br />
Agilent Technologies | 30/06/2022 | By Sudeep Soparkar | 545
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy